Activated protein C action in inflammation
Open Access
- 1 March 2010
- journal article
- review article
- Published by Wiley in British Journal of Haematology
- Vol. 148 (6), 817-833
- https://doi.org/10.1111/j.1365-2141.2009.08020.x
Abstract
Activated protein C (APC) is a natural anticoagulant that plays an important role in coagulation homeostasis by inactivating the procoagulation factor Va and VIIIa. In addition to its anticoagulation functions, APC also has cytoprotective effects such as anti‐inflammatory, anti‐apoptotic, and endothelial barrier protection. Recently, a recombinant form of human APC (rhAPC or drotrecogin alfa activated; known commercially as ‘Xigris’) was approved by the US Federal Drug Administration for treatment of severe sepsis associated with a high risk of mortality. Sepsis, also known as systemic inflammatory response syndrome (SIRS) resulting from infection, is a serious medical condition in critical care patients. In sepsis, hyperactive and dysregulated inflammatory responses lead to secretion of pro‐ and anti‐inflammatory cytokines, activation and migration of leucocytes, activation of coagulation, inhibition of fibrinolysis, and increased apoptosis. Although initial hypotheses focused on antithrombotic and profibrinolytic functions of APC in sepsis, other agents with more potent anticoagulation functions were not effective in treating severe sepsis. Furthermore, APC therapy is also associated with the risk of severe bleeding in treated patients. Therefore, the cytoprotective effects, rather than the anticoagulant effect of APC are postulated to be responsible for the therapeutic benefit of APC in the treatment of severe sepsis.Keywords
This publication has 143 references indexed in Scilit:
- Protective mechanisms of activated protein C in severe inflammatory disordersBritish Journal of Pharmacology, 2009
- Extended drotrecogin alfa (activated) treatment in patients with prolonged septic shockIntensive Care Medicine, 2009
- Activated protein C ligation of ApoER2 (LRP8) causes Dab1-dependent signaling in U937 cellsProceedings of the National Academy of Sciences of the United States of America, 2009
- Harmful molecular mechanisms in sepsisNature Reviews Immunology, 2008
- Randomized Clinical Trial of Activated Protein C for the Treatment of Acute Lung InjuryAmerican Journal of Respiratory and Critical Care Medicine, 2008
- Endotoxemia and sepsis mortality reduction by non-anticoagulant–activated protein CThe Journal of Experimental Medicine, 2007
- Proteolysis of the endothelial cell protein C receptor by neutrophil proteinase 3Journal of Thrombosis and Haemostasis, 2007
- Receptors of the protein C activation and activated protein C signaling pathways are colocalized in lipid rafts of endothelial cellsProceedings of the National Academy of Sciences of the United States of America, 2007
- Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotectiveNature Medicine, 2003
- Integrins: Versatility, modulation, and signaling in cell adhesionCell, 1992